Mergers & Acquisitions ·
Esperion Therapeutics, Inc. consummated a merger-based acquisition by Essence Parent Inc. on July 13, 2026, for…
ESPREsperion Therapeutics, Inc.
Esperion Therapeutics, Inc. consummated a merger-based acquisition by Essence Parent Inc. on July 13, 2026, for approximately $1.1 billion in cash, plus the issuance of Contingent Value Rights (CVRs). Shareholders of common stock were entitled to receive $3.16 per share in cash and one CVR per share, representing a right to participate in contingent cash payments of up to $0.1 billion in the aggregate. The company's common stock will be delisted from the Nasdaq Stock Market LLC. Esperion Therapeutics, Inc. is a biopharmaceutical company focused on cardiovascular disease management.